Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
ABSTRACT FROM: Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry 2015;72:822–9.
What is already known on this topic
Appropriate use of antipsychotic medications for people experiencing early episode psychosis is critical for symptom control and for shaping attitudes towards medication as a support to recovery.1 Risperidone is an effective medication in treating early episode psychosis2 and long-acting injectable risperidone may increase early (12-week) adherence rates.3 However, long-acting medications are rarely used following a first episode of schizophrenia4 and the aim of the present study was to compare the clinical efficacy of the long-acting injectable formulation of risperidone with the oral formulation in the early course of schizophrenia.
Methods of the study
Eighty-three people with early episode schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV)) in the Los Angeles area participated between …
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.